Roche’s Ocrevus more effective than Merck’s Rebif, company claims

Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The data will be presented during the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) this week in London.
read more

Filed under: MS

Why Juno Therapeutics Could Be The Future Leader In CAR-T And TCR Immune-Oncology Space

Filed under: Cancer, Immunotherapy

Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business

[GlobeNewswire] – -Transaction valued at $9.00 per share in cash with fully diluted equity value of approximately $800 million-. -Transaction is expected to be accretive to adjusted EBITDA in 2017-. -Conference call today …

Filed under: Company

How Congress Can Make Drug Pricing More Rational

The public reproach over the price of Mylan’s lifesaving drug EpiPen is the latest imbroglio in a much broader debate over drug costs. At issue is the rising list price on drugs. But as Mylan argued, these high reported prices often bear little relation to the real price actually paid, after rebates and discounts, by most health plans.

Filed under: Pricing

Sanofi, Verily Life Sciences create new JV to develop diabetes management platform

French pharmaceutical firm Sanofi and Alphabet subsidiary Verily Life Sciences have launched a new joint venture (JV), Onduo, to develop comprehensive diabetes management platform.

Filed under: Diabetes

Express Scripts Adds Diabetes, Inflammatory Drugs to Value Pricing Plan

ArticleThe issue of high drug prices has raised a number of concerns with insurers and employers searching for strategies to provide patients with the most cost-effective payment plans. Staff Author: Ryan BusheyTopics: Legal/Regulatory

Filed under: Payer

J&J, Achillion aim for best-in-class with early HCV data

J&J, Achillion aim for best-in-class with early HCV data
Fri, 09/09/2016 – 10:07

Filed under: HCV

Priority review for Merck’s Keytruda in first-line NSCLC

US regulators have agreed to undertake a priority review of Merck’s application to market its immunotherapy Keytruda for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours express PD-L1.

Filed under: Cancer, Immunotherapy

Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Index for the eighth year running

For the eighth consecutive year, Roche has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry of the Dow Jones Sustainability Index (DJSI).

Filed under: Company

AstraZeneca to explore link between epigenetics and respiratory diseases

Joins forces with Asthma UK, the British
Lung Foundation and MRC Technology

Filed under: Respiratory

UK launch for Biogen’s biosimilar infliximab

Biogen has launched Flixabi – a biosimilar of Johnson & Johnson’s blockbuster infliximab – across the UK for use in a range of chronic inflammatory conditions.

Filed under: Biosimilar

GSK announce positive results from the COPD Salford Lung Study

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar® Ellipta® in patients with chronic obstructive pulmonary disease (COPD), compared with their ‘usual care’ administered in an everyday clinical practice setting.

Filed under: COPD

Amgen, Servier advance cardiovascular collaboration

Amgen and Servier last week announced that their cardiovascular collaboration
has seen an advancement due to Servier deciding to exercise its option for the
commercialization of omecamtiv mecarbil in Europe for chronic heart failure.

Filed under: Company

European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate

[Business Wire] – Bristol-Myers Squibb Company today announced that the European Commission has approved ORENCIA® intravenous infusion and subcutaneous injection, in combination with methotrexate , for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with MTX.

Filed under: Arthritis

Biogen’s Alzheimer’s Therapy Granted FDA Fast-Track Status

Filed under: Alzheimer’s

Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE® immuno-oncology drug for multiple myeloma

Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma.

Filed under: Cancer, Immunotherapy

US expands use of Novartis/Genmab’s Arzerra

US regulators have expanded the approved uses of Novartis/Genmab’s Arzerra so that the biologic can now be used alongside fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukaemia.

Filed under: Cancer

Novo Nordisk chief retires in shake-up

Danish group faces pricing pressure for core diabetes drugs

Filed under: Company

ESC: Effient and Brilinta Equal for Post-MI Prevention

(MedPage Today) — PRAGUE-18 trial underpowered but enough to prove no big difference

Filed under: Cardiovascular

Pfizer’s Xalkori gets European approval for ROS1-positive advanced NSCLC

Pfizer has secured approval from the European Commission (EC) for Xalkori (crizotinib) to treat adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).

Filed under: Cancer